This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Colon Cancer  • Oncology, Other  • Radiation Therapy  • Colorectal Surgery  • Surgical Oncology  • Prognosis/ Outcomes  • Gastrointestinal Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Eric T. Castaldo, MD, MPH; Alexander A. Parikh, MD; C. Wright Pinson, MD, MBA; Irene D. Feurer, PhD; Nipun B. Merchant, MD

Arch Surg. 2009;144(2):129-134.

Objectives  To determine whether patients with a complete or near-complete response to neoadjuvant radiation therapy (XRT) have improved survival compared with those with less of a response and to compare survival between patients with disease downstaged after neoadjuvant XRT and patients with stage I disease undergoing resection alone.

Design, Setting, and Patients  Retrospective cohort of 10 971 patients (3760 patients with neoadjuvant XRT; 7211 with stage I disease with resection alone) from the Surveillance, Epidemiology, and End Results registry using data from January 1, 1994, through December 31, 2003.

Main Outcome Measures  Overall survival and disease-specific survival (DSS) of patients undergoing resection for nonmetastatic rectal adenocarcinoma receiving neoadjuvant XRT and patients with stage I disease undergoing surgical resection alone.

Results  The 5-year DSS and overall survival were 94% and 82%, respectively, for responders to neoadjuvant XRT, 78% and 60%, respectively, for nonresponders, and 97% and 79%, respectively, for patients with stage I disease undergoing resection alone. Responders had improved DSS (P < .001) and overall survival (P < .001) compared with nonresponders by Cox regression. Patients with stage I disease undergoing resection alone had improved DSS (P = .01) but not overall survival (P = .89) compared with XRT responders.

Conclusions  Patients with rectal adenocarcinoma downstaged after neoadjuvant XRT have improved survival compared with nonresponders. While DSS is excellent for responders to neoadjuvant XRT, it did not equal the DSS of patients with stage I disease undergoing resection alone.

Author Affiliations: Divisions of Hepatobiliary Surgery and Liver Transplantation (Drs Castaldo, Pinson, and Feurer) and Surgical Oncology (Drs Parikh and Merchant), Department of Surgery, and Department of Biostatistics (Dr Feurer), Vanderbilt University Medical Center, Nashville, Tennessee.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Improvement of Survival With Response to Neoadjuvant Radiation Therapy for Rectal Cancer—Invited Critique
Harvey G. Moore
Arch Surg. 2009;144(2):134-135.
EXTRACT | FULL TEXT